Home Featured Page 249

Featured

Latest

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

Psychedelic Futures – Nowak Society featuring Joe Moore

Q2 2025: Oregon Psilocybin Services Update

Webinar with Tim Cools of Psychedelic Experience

Lobe Sciences Secures Production and Supply Agreement for Vitamind Consumer Packaged...

Mydecine Provides Update on Spin-Out of U.S. Cannabis Assets

MINDCURE Appoints Dr. John Brownstein, the Chief Innovation Officer at Boston...

Tryp Therapeutics Partners with Clinlogix for Clinical Trial Support

The Chopra Foundation and MindMed Enter Into Letter of Intent to...

Cybin Granted IRB Approval for Phase II Clinical Trials of its...

Entheon Biomedical Announces DMT Drug Supply Agreement with Ofichem Group

PT244 – Mark Haberstroh – Mushrooms, Retreat Centers, and Safety

1...248249250...299 Page 249 of 299

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

Psychedelic Futures – Nowak Society featuring Joe Moore

Q2 2025: Oregon Psilocybin Services Update

Webinar with Tim Cools of Psychedelic Experience

Lobe Sciences Secures Production and Supply Agreement for Vitamind Consumer Packaged...

What Is Sacred Reciprocity?

Mydecine Provides Update on Spin-Out of U.S. Cannabis Assets

MINDCURE Appoints Dr. John Brownstein, the Chief Innovation Officer at Boston...

Tryp Therapeutics Partners with Clinlogix for Clinical Trial Support

The Chopra Foundation and MindMed Enter Into Letter of Intent to...

Cybin Granted IRB Approval for Phase II Clinical Trials of its...

Entheon Biomedical Announces DMT Drug Supply Agreement with Ofichem Group

PT244 – Mark Haberstroh – Mushrooms, Retreat Centers, and Safety

EDITOR PICKS

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY